How VX-407 interacts with common birth control pills

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 study evaluates the pharmacokinetics, safety, and tolerability of VX-407 when taken with combined oral contraceptives. Participants receive VX-407 alongside LNG/EE, NGM/EE, NET/EE, or DRSP/EE, with careful monitoring of drug levels and any adverse effects. The trial helps determine if dosing or contraceptive effectiveness could be impacted when VX-407 is used concurrently with these medications. Eligibility includes adults with BMI 18–30 kg/m2 and body weight over 50 kg; key exclusions include recent febrile illness and pregnancy or plans for pregnancy during or shortly after the study.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2), inclusive
* A total body weight of greater than (\>) 50 kg

Key Exclusion Criteria:

* History of febrile illness within 5 days before the first dose of study drug
* Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug

Other protocol defined Inclusion/Exclusion criteria will apply.

Where it's running

• Altasciences - Beaumont Clinic Montreal
  Montreal, Canada Recruiting

Study contacts

• Study coordinator: Medical Information
• Email: medicalinfo@vrtx.com
• Phone: 617-341-6777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VX-407 pharmacokinetics after a single dose in adults with ADPKD

  This study tests how VX-407 is absorbed, distributed, metabolized, and excreted after a one-time oral dose in adults with polycystic kidney disease.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Lincoln, Nebraska · NCT07868926

• Renal embolization with EVOH for adults on dialysis with ADPKD

  This study tests whether blocking blood flow to very large polycystic kidneys with the liquid embolic EVOH can shrink kidney size and reduce symptoms in adults on dialysis with ADPKD.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07535385

• Ren-Nu: a kidney-focused ketogenic diet program for people with polycystic kidney disease

  This 16-week pilot will try a dietitian-led, kidney-safe ketogenic program plus KetoCitra in adults with ADPKD to improve metabolic health.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07454174

• High blood pressure in children and teenagers at risk of ADPKD

  This project will use MRI, blood tests, arterial stiffness measures, and ambulatory blood pressure monitoring to see how common high blood pressure is in 12–17-year-olds who have a parent with ADPKD.

  Recruiting King's College London · London · NCT07260071

• Evaluating the safety of PYC-003 for treating a kidney disease

  This study is testing a new drug called PYC-003 to see if it's safe for people with a specific type of kidney disease and healthy adults.

  Recruiting at 12 sites Phase 1 PYC Therapeutics · Southport, Gold Coast and 11 other locations · NCT06714006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.